Dexibufen softcap
Dexibuprofen 400mg
Denesity (Lyodura 200mg)
Acid alpha lipoic 200 mg
Catolis
Ursodeoxycholic acid 150mg
BLESSMOM
Magnesium pidolate /Rhodiola extract /Vitamin B6, B12 /Zinc gluconate /Folic acid
Dexibuprofen 400mg
Soft capsule
For the fast and effective reduction of fever, including post immunisation pyrexia and the fast and effective relief of the symptoms of colds and influenza and mild to moderate pain, such as a sore throat, teething pain, toothache, dental pain, headache, minor aches and sprains, rheumatic and muscular pain.
Children and adolescents between 12 and 18 years: Take 1 capsule with water, up to three times a day as required.
Adults: Take 1 capsule with water, up to three times a day as required.
Leave at least 4 hours between doses.
Do not take more than 3 capsules in 24 hour.
Acid alpha lipoic 200 mg
Soft capsule
Support for the prevention of neurologic complications, cataracts, infection, degeneration of the retina in diabetes patients
- Treatment of sensory disorders due to diabetic polyneuropathy: Take 1 time only once every 30 minutes before breakfast
- Prevention of neurological complications, cataract complications, retinal degeneration, infections of diabetes: 1 capsule / time x 2-3 times / day.
- Supportive treatment of diabetes: 1 capsule / time x 2-3 times / day.
Ursodeoxycholic acid 150mg
Soft capsule
Primary biliary cirrhosis (PBC) and for the dissolution of small to medium sized radiolucent, cholesterol-rich gall-stones in patients with a functioning gall bladder.
Catolis has a particular place in the treatment of patients in whom surgery is contraindicated or who are anxious to avoid surgery.
Paediatric population
Hepatobiliar disorder associated with cystic fibrosis in children aged 6 years to less than 18 years.
Dosage: The dosage should be calculated based on the patient's body weight. The calculated dosage should be rounded to the nearest number of tablets.
Dissolving of cholesterol stones:
Usual dosage: 8 to 10 mg/kg/day, corresponding to, for example, four to six 150 mg tablets, or two to three tablets of 300 mg, or two tablets of 450 mg. The daily dose can be administered two or three times after the meals: two tablets should always be taken after the evening meal.
Children with cystic fibrosis aged 6 years to 18 years:
Treatment of hepatobiliary diseases as a result of cystic fibrosis 20 mg/kg/day divided in two to three divided doses. If necessary, increase to 30 mg/kg/day. This corresponds with four to ten tablets of 150mg, two to five tablets of 300 mg, or with two to three tablets of 450 mg, to be taken in one or two portions during the day.
Each capsule contains:
Magnesium pidolate 292 mg
Rhodiola extract 100 mg, Vitamin B6 50 mg
Zinc gluconate 21 mg
Vitamin B12 200 mcg
Folic acid 50 mcg
Soft capsule
Support sedation, help relieve symptoms of stress, anxiety, fatigue
Subject to use:
Pregnant and postpartum women have feelings of nervous stress, anxiety and sadness
1-2 capsules/time, twice a day, depending on the condition, according to the physician's instructions.
Biosoft
Biotin (vitamin H) 10mg
Beenenit (Verni - topbee 300)
Ursodeoxycholic acid 300mg
ARICAMUN
Isotretinoin 20mg
Biotin (vitamin H) 10mg
Soft capsule
Hair loss, seborrheic dermatitis, skin symptoms caused by lack of B vitamins.
- Maintenance treatment for alopecia and scalp secretion: Take 3 capsules daily for 2 months.
- Children 1-2 tablets / day.
- Adults 2-4 tablets / day
Ursodeoxycholic acid 300mg
Soft capsule
Primary biliary cirrhosis (PBC) and for the dissolution of small to medium sized radiolucent, cholesterol-rich gall-stones in patients with a functioning gall bladder.
Vernitopbee 300 has a particular place in the treatment of patients in whom surgery is contraindicated or who are anxious to avoid surgery.
Paediatric population
Hepatobiliar disorder associated with cystic fibrosis in children aged 6 years to less than 18 years.
Each soft capsule contains Isotretinoin 20 mg.
Excipient(s) with known effect
Soya Oil: 208.4 mg/capsule
Soft capsules
Severe forms of acne (such as nodular or conglobate acne or acne at risk of permanent scarring) resistant to adequate courses of standard therapy with systemic antibacterials and topical therapy.
Posology
Aricamun should only be prescribed by or under the supervision of physicians with expertise in the use of systemic retinoids for the treatment of severe acne and a full understanding of the risks of Aricamun therapy and monitoring requirements.
The capsules should be taken with food once or twice daily.
Adults including adolescents and the elderly:
Aricamun therapy should be started at a dose of 0.5 mg/kg daily. The therapeutic response to Aricamun and some of the adverse effects are dose-related and vary between patients. This necessitates individual dosage adjustment during therapy. For most patients, the dose ranges from 0.5-1.0 mg/kg per day.
Long-term remission and relapse rates are more closely related to the total dose administered than to either duration of treatment or daily dose. It has been shown that no substantial additional benefit is to be expected beyond a cumulative treatment dose of 120-150 mg/kg. The duration of treatment will depend on the individual daily dose. A treatment course of 16-24 weeks is normally sufficient to achieve remission.
In the majority of patients, complete clearing of the acne is obtained with a single treatment course. In the event of a definite relapse a further course of Aricamun therapy may be considered using the same daily dose and cumulative treatment dose. As further improvement of the acne can be observed up to 8 weeks after discontinuation of treatment, a further course of treatment should not be considered until at least this period has elapsed.
Patients with renal impairment
In patients with severe renal insufficiency treatment should be started at a lower dose (e.g. 10 mg/day). The dose should then be increased up to 1 mg/kg/day or until the patient is receiving the maximum tolerated dose
Paediatric population
Aricamun is not indicated for the treatment of prepubertal acne and is not recommended in patients less than 12 years of age due to a lack of data on efficacy and safety.
Patients with intolerance
In patients who show severe intolerance to the recommended dose, treatment may be continued at a lower dose with the consequences of a longer therapy duration and a higher risk of relapse. In order to achieve the maximum possible efficacy in these patients the dose should normally be continued at the highest tolerated dose.
Method of administration
Oral use.
Dexibufen softcap
Dexibuprofen 400mg
Denesity (Lyodura 200mg)
Acid alpha lipoic 200 mg
Dexibuprofen 400mg
Soft capsule
For the fast and effective reduction of fever, including post immunisation pyrexia and the fast and effective relief of the symptoms of colds and influenza and mild to moderate pain, such as a sore throat, teething pain, toothache, dental pain, headache, minor aches and sprains, rheumatic and muscular pain.
Children and adolescents between 12 and 18 years: Take 1 capsule with water, up to three times a day as required.
Adults: Take 1 capsule with water, up to three times a day as required.
Leave at least 4 hours between doses.
Do not take more than 3 capsules in 24 hour.
Acid alpha lipoic 200 mg
Soft capsule
Support for the prevention of neurologic complications, cataracts, infection, degeneration of the retina in diabetes patients
- Treatment of sensory disorders due to diabetic polyneuropathy: Take 1 time only once every 30 minutes before breakfast
- Prevention of neurological complications, cataract complications, retinal degeneration, infections of diabetes: 1 capsule / time x 2-3 times / day.
- Supportive treatment of diabetes: 1 capsule / time x 2-3 times / day.
Catolis
Ursodeoxycholic acid 150mg
BLESSMOM
Magnesium pidolate /Rhodiola extract /Vitamin B6, B12 /Zinc gluconate /Folic acid
Ursodeoxycholic acid 150mg
Soft capsule
Primary biliary cirrhosis (PBC) and for the dissolution of small to medium sized radiolucent, cholesterol-rich gall-stones in patients with a functioning gall bladder.
Catolis has a particular place in the treatment of patients in whom surgery is contraindicated or who are anxious to avoid surgery.
Paediatric population
Hepatobiliar disorder associated with cystic fibrosis in children aged 6 years to less than 18 years.
Dosage: The dosage should be calculated based on the patient's body weight. The calculated dosage should be rounded to the nearest number of tablets.
Dissolving of cholesterol stones:
Usual dosage: 8 to 10 mg/kg/day, corresponding to, for example, four to six 150 mg tablets, or two to three tablets of 300 mg, or two tablets of 450 mg. The daily dose can be administered two or three times after the meals: two tablets should always be taken after the evening meal.
Children with cystic fibrosis aged 6 years to 18 years:
Treatment of hepatobiliary diseases as a result of cystic fibrosis 20 mg/kg/day divided in two to three divided doses. If necessary, increase to 30 mg/kg/day. This corresponds with four to ten tablets of 150mg, two to five tablets of 300 mg, or with two to three tablets of 450 mg, to be taken in one or two portions during the day.
Each capsule contains:
Magnesium pidolate 292 mg
Rhodiola extract 100 mg, Vitamin B6 50 mg
Zinc gluconate 21 mg
Vitamin B12 200 mcg
Folic acid 50 mcg
Soft capsule
Support sedation, help relieve symptoms of stress, anxiety, fatigue
Subject to use:
Pregnant and postpartum women have feelings of nervous stress, anxiety and sadness
1-2 capsules/time, twice a day, depending on the condition, according to the physician's instructions.
Biosoft
Biotin (vitamin H) 10mg
Beenenit (Verni - topbee 300)
Ursodeoxycholic acid 300mg
Biotin (vitamin H) 10mg
Soft capsule
Hair loss, seborrheic dermatitis, skin symptoms caused by lack of B vitamins.
- Maintenance treatment for alopecia and scalp secretion: Take 3 capsules daily for 2 months.
- Children 1-2 tablets / day.
- Adults 2-4 tablets / day
Ursodeoxycholic acid 300mg
Soft capsule
Primary biliary cirrhosis (PBC) and for the dissolution of small to medium sized radiolucent, cholesterol-rich gall-stones in patients with a functioning gall bladder.
Vernitopbee 300 has a particular place in the treatment of patients in whom surgery is contraindicated or who are anxious to avoid surgery.
Paediatric population
Hepatobiliar disorder associated with cystic fibrosis in children aged 6 years to less than 18 years.
ARICAMUN
Isotretinoin 20mg
Each soft capsule contains Isotretinoin 20 mg.
Excipient(s) with known effect
Soya Oil: 208.4 mg/capsule
Soft capsules
Severe forms of acne (such as nodular or conglobate acne or acne at risk of permanent scarring) resistant to adequate courses of standard therapy with systemic antibacterials and topical therapy.
Posology
Aricamun should only be prescribed by or under the supervision of physicians with expertise in the use of systemic retinoids for the treatment of severe acne and a full understanding of the risks of Aricamun therapy and monitoring requirements.
The capsules should be taken with food once or twice daily.
Adults including adolescents and the elderly:
Aricamun therapy should be started at a dose of 0.5 mg/kg daily. The therapeutic response to Aricamun and some of the adverse effects are dose-related and vary between patients. This necessitates individual dosage adjustment during therapy. For most patients, the dose ranges from 0.5-1.0 mg/kg per day.
Long-term remission and relapse rates are more closely related to the total dose administered than to either duration of treatment or daily dose. It has been shown that no substantial additional benefit is to be expected beyond a cumulative treatment dose of 120-150 mg/kg. The duration of treatment will depend on the individual daily dose. A treatment course of 16-24 weeks is normally sufficient to achieve remission.
In the majority of patients, complete clearing of the acne is obtained with a single treatment course. In the event of a definite relapse a further course of Aricamun therapy may be considered using the same daily dose and cumulative treatment dose. As further improvement of the acne can be observed up to 8 weeks after discontinuation of treatment, a further course of treatment should not be considered until at least this period has elapsed.
Patients with renal impairment
In patients with severe renal insufficiency treatment should be started at a lower dose (e.g. 10 mg/day). The dose should then be increased up to 1 mg/kg/day or until the patient is receiving the maximum tolerated dose
Paediatric population
Aricamun is not indicated for the treatment of prepubertal acne and is not recommended in patients less than 12 years of age due to a lack of data on efficacy and safety.
Patients with intolerance
In patients who show severe intolerance to the recommended dose, treatment may be continued at a lower dose with the consequences of a longer therapy duration and a higher risk of relapse. In order to achieve the maximum possible efficacy in these patients the dose should normally be continued at the highest tolerated dose.
Method of administration
Oral use.